ES2521674T3 - Métodos de tratamiento de hiperuricemia y estados patológicos asociados - Google Patents
Métodos de tratamiento de hiperuricemia y estados patológicos asociados Download PDFInfo
- Publication number
- ES2521674T3 ES2521674T3 ES09792556.4T ES09792556T ES2521674T3 ES 2521674 T3 ES2521674 T3 ES 2521674T3 ES 09792556 T ES09792556 T ES 09792556T ES 2521674 T3 ES2521674 T3 ES 2521674T3
- Authority
- ES
- Spain
- Prior art keywords
- patient
- hyperuricemia
- treatment
- methods
- pathological conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 3
- 229940116269 uric acid Drugs 0.000 abstract 3
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 abstract 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97023P | 1998-08-18 | ||
| US9702308P | 2008-09-15 | 2008-09-15 | |
| PCT/US2009/056985 WO2010031051A1 (en) | 2008-09-15 | 2009-09-15 | Methods of treatment of hyperuricemia and associated disease states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2521674T3 true ES2521674T3 (es) | 2014-11-13 |
Family
ID=41319433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09792556.4T Active ES2521674T3 (es) | 2008-09-15 | 2009-09-15 | Métodos de tratamiento de hiperuricemia y estados patológicos asociados |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8748496B2 (enExample) |
| EP (1) | EP2349280B1 (enExample) |
| JP (1) | JP5685192B2 (enExample) |
| AR (1) | AR073514A1 (enExample) |
| AU (1) | AU2009290612B2 (enExample) |
| CA (1) | CA2737163C (enExample) |
| ES (1) | ES2521674T3 (enExample) |
| TW (1) | TW201016208A (enExample) |
| WO (2) | WO2010031051A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| KR20080009111A (ko) | 2005-04-11 | 2008-01-24 | 새비언트 파마수티컬즈 인크. | 유레이트 옥시다아제의 변이형 및 이의 용도 |
| AU2010265964B2 (en) | 2009-06-25 | 2014-09-18 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
| CN102726721A (zh) * | 2011-12-21 | 2012-10-17 | 聂存良 | 一种平衡性的微量元素排铅口服液 |
| US20160303050A1 (en) * | 2015-04-20 | 2016-10-20 | Twi Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
| CN110234340A (zh) * | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN109666687B (zh) * | 2018-12-14 | 2020-08-04 | 艾美科健（中国）生物医药有限公司 | 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用 |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998485A (en) * | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| EP1824496A4 (en) * | 2004-11-17 | 2008-07-16 | Joanne Mclaurin | COMPOSITIONS OF SCYLLO-INOSITOL DERIVATIVES AND METHOD FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS |
| CA2674048A1 (en) * | 2006-12-29 | 2008-07-10 | Normoxys, Inc. | Cyclitols and their derivatives and their therapeutic applications |
-
2009
- 2009-09-15 EP EP09792556.4A patent/EP2349280B1/en active Active
- 2009-09-15 JP JP2011527043A patent/JP5685192B2/ja active Active
- 2009-09-15 TW TW098131051A patent/TW201016208A/zh unknown
- 2009-09-15 AU AU2009290612A patent/AU2009290612B2/en active Active
- 2009-09-15 CA CA2737163A patent/CA2737163C/en active Active
- 2009-09-15 WO PCT/US2009/056985 patent/WO2010031051A1/en not_active Ceased
- 2009-09-15 AR ARP090103535A patent/AR073514A1/es unknown
- 2009-09-15 WO PCT/US2009/057003 patent/WO2010031061A1/en not_active Ceased
- 2009-09-15 ES ES09792556.4T patent/ES2521674T3/es active Active
- 2009-09-15 US US12/560,113 patent/US8748496B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2349280B1 (en) | 2014-07-30 |
| JP5685192B2 (ja) | 2015-03-18 |
| US8748496B2 (en) | 2014-06-10 |
| CA2737163A1 (en) | 2010-03-18 |
| EP2349280A1 (en) | 2011-08-03 |
| WO2010031061A1 (en) | 2010-03-18 |
| AU2009290612B2 (en) | 2015-05-14 |
| WO2010031051A1 (en) | 2010-03-18 |
| US20100152305A1 (en) | 2010-06-17 |
| AR073514A1 (es) | 2010-11-10 |
| AU2009290612A1 (en) | 2010-03-18 |
| CA2737163C (en) | 2019-03-12 |
| TW201016208A (en) | 2010-05-01 |
| JP2012502914A (ja) | 2012-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2521674T3 (es) | Métodos de tratamiento de hiperuricemia y estados patológicos asociados | |
| Escobedo et al. | Restoration of lymphatic function rescues obesity in Prox1-haploinsufficient mice | |
| ES2509892T3 (es) | Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal | |
| EA201070465A1 (ru) | Устройство для управления потоком в органе тела | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| BRPI0911923A8 (pt) | dispositivos filamentares para tratamento de defeitos vasculares | |
| CL2007003648A1 (es) | Metodo para el tratamiento o profilaxis de infeccion por circovirus 2 porcino (pcv2) o para la reduccion de los sintomas clinicos asociados a pcv2 en animales que tienen anticuerpos anti-pcv2 y/o que tienen 1 a 22 dias de edad que comprende administr | |
| CR10169A (es) | "uso de derivados de sulfamida heterociclica benzo-fusionada para disminuir lipidos y disminuir niveles de glucosa en la sangre" | |
| CO6592030A2 (es) | Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa | |
| AR085837A1 (es) | Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer | |
| AR054909A1 (es) | Modulacion de los receptores activados por el proliferador de peroxisomas | |
| RU2009139734A (ru) | Способ прогнозирования сосудистых нарушений у больных с эссенциальной артериальной гипертонией | |
| ES2647895T3 (es) | Método para evaluar la celulitis y método para evaluar la eficacia de un fármaco contra la celulitis empleando fibulina-3 y/o sarcoglicano gamma como indicador | |
| ES2578729T3 (es) | Agente terapéutico para enfermedades relacionadas con el hígado | |
| CN218651905U (zh) | 一种新型的输尿管膀胱吻合装置 | |
| AR129944A1 (es) | Uso de compuestos que contienen manganeso para reducir el nivel de ácido úrico en sujetos mamíferos; una composición; un kit y un método de prevención y/o tratamiento | |
| RU2004136472A (ru) | Способ лечения хронических диффузных заболеваний печени | |
| Solanki et al. | Pedicled gracilis myocutaneous flap for treatment of recalcitrant hidradenitis suppurativa of the groin and perineum | |
| Mueller et al. | Mandibular reconstruction with microvascular re-anastomosed fibular free flaps–Two complementary methods of postoperative transplant monitoring | |
| Tanaka et al. | Serum S100B is a useful surrogate marker for long-term outcomes in photochemically-induced thrombotic stroke rat models | |
| von Preussen et al. | Acne inversa successfully treated with infliximab. | |
| JP5840193B2 (ja) | 死体保存用注入液 | |
| RU2007148194A (ru) | Способ выбора тактики лечения у больных с хронической ишемией головного мозга | |
| RU163270U1 (ru) | Устройство для компрессионного гемостаза при внутрибрюшных кровотечениях | |
| Cho | Physiological and Pharmacological Maneuvers to Rejuvenate Age-Associated Cardiovascular Dysfunction |